drugset / Trial / NCT00790114

Determine the Effect of Multiple Doses of AZD7325, CYP Study

NCT00790114

Phase 1 Completed 24 enrolled AstraZeneca
RandomizedSingle-groupQuadruple-blind

Summary

To determine the effects of repeated doses of AZD7325 on the pharmacokinetic profile of a CYP3A4 substrate (midazolam and its 1' hydroxy metabolite) and a CYP1A2 substrate (caffeine and its paraxanthine \[3-desmethyl\] metabolite).

Timeline

Start
2008-07
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7325 Small molecule Oral
Subject Caffeine Small molecule
Subject Midazolam Small molecule

Indications

No indication recorded.